Market Scope

Trusted Partner of Industry and Medical Professionals for Ophthalmic Market Data, Primary Research, Independent Perspective, & Objective Analysis

Latest Reports Latest News

Latest Market Reports

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.

Latest Industry News & Trends

8/5/2022
BreakingPharmaRegulationRetina
US FDA Approves Coherus’ Lucentis Biosimilar, Branded Cimerli
US FDA Approves Coherus’ Lucentis Biosimilar, Branded Cimerli

Coherus BioSciences announced Aug. 2 that the US FDA had approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection). Cimerli is approved for a...

8/5/2022
BreakingCataractDry EyeGlaucomaPresbyopiaRetinaRevenue
Q2-2022 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, AbbVie, and Three Others
Q2-2022 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, AbbVie, and Three Others

Regeneron of Tarrytown, New York, reported Aug. 3 that its Q2-2022 US revenue for Eylea was a record $1.62 billion, a 14 percent increase over $1.42 billion in Q2-2021. Regeneron’s collaboration re...

8/5/2022
BreakingGlaucomaRegulationSurgical
Glaukos Gains US FDA 510(k) Clearance for iStent Infinite
Glaukos Gains US FDA 510(k) Clearance for iStent Infinite

Glaukos announced Aug. 3 that it had received 510(k) clearance from the US FDA for its iStent Infinite trabecular micro-bypass system. The iStent Infinite is indicated for use in a standalone proce...

8/5/2022
BreakingClinical TrialRetina
OcuTerra Doses First Patient in Phase II Trial of Topical DR Candidate
OcuTerra Doses First Patient in Phase II Trial of Topical DR Candidate

OcuTerra Therapeutics announced Aug. 2 that the first patient had been dosed in a Phase II clinical trial evaluating its OTT166 eye drop in adults with moderately severe to severe non-proliferative...

8/8/2022
BreakingPharmaRegulation
US Senate Passes Bill That Allows Medicare to Negotiate Prices for Some Drugs
US Senate Passes Bill That Allows Medicare to Negotiate Prices for Some Drugs

The US Senate on Aug. 7 passed legislation that empowers Medicare to negotiate prescription drug prices on some drugs starting in 2023. Senators passed the Inflation Reduction Act with a 50-50 part...

8/5/2022
BreakingClinical TrialDry Eye
Aerie Doses First Patient in Phase III COMET-3 Study of its TRPM8 Agonist for Dry Eye
Aerie Doses First Patient in Phase III COMET-3 Study of its TRPM8 Agonist for Dry Eye

Aerie Pharmaceuticals, maker of Rhopressa and Rocklatan for glaucoma, announced Aug. 1 that it had dosed the first patient in the Phase III COMET-3 study of its AR-15512 ophthalmic solution in dry ...

8/5/2022
BreakingClinical TrialPharmaRetina
EyePoint Doses First Patient in Phase II Trial of EYP-1901 in Wet AMD
EyePoint Doses First Patient in Phase II Trial of EYP-1901 in Wet AMD

EyePoint Pharmaceuticals, maker of Yutiq and Dexycu, announced Aug. 1 that it had dosed the first patient in the Phase II DAVIO 2 trial of EYP-1901 in wet age-related macular degeneration (wet AMD)...

8/5/2022
BreakingClinical TrialGene TherapyRetina
Nanoscope Doses First Patient in Phase II Trial of Optogenetic Stargardt Candidate
Nanoscope Doses First Patient in Phase II Trial of Optogenetic Stargardt Candidate

Nanoscope Therapeutics announced July 25 that the first patient had been dosed in a Phase II trial of its of its optogenetic monotherapy in Stargardt patients. The Dallas company is advancing Multi...

Physician Surveys

For 20+ years, we have surveyed physicians to provide both physicians & industry professionals unbiased insight into the market.

Complete a Survey

On average, our surveys take only 5 to 15 minutes to complete. Survey results help you analyze practice patterns, evaluate treatment choices, and benchmark your practice.

Benchmark Your Performance

Benchmark reports allow you to gauge your performance, track your practice metrics over time, and compare your practice to national averages.

View Market Insights & Analytics

Additional free data tools include instant survey results, weekly polls, PowerPoint charts, and more.

Learn More Register Today

Market Scope Methodology

A Multi-Step Approach for Accurate & Timely Data

Proprietary data

  • 20+ years of physician survey data
  • Disease models
  • Cultivated database of physicians, ASCs, and hospitals
  • Insight from our team of in-house industry experts

Public data

  • Attendance and participation at major, worldwide meetings
  • Public health systems and registries
  • Clinical study data
  • Analysis of company-published financial reports

Over 500 Clients, Large & Small, Have Trusted Market Scope Data & Analysis

Join Market Scope Today

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more

Register A Clinical Account

A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.

United States
US Surveys
May select more than one